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Validation of Claims Data Algorithms to Identify
Nonmelanoma Skin Cancer
Melody J. Eide1,2, J. Mark Tuthill3, Richard J. Krajenta2, Gordon R. Jacobsen2, Marc Levine3 and
Christine C. Johnson2
Health maintenance organization (HMO) administrative databases have been used as sampling frames for
ascertaining nonmelanoma skin cancer (NMSC). However, because of the lack of tumor registry information on
these cancers, these ascertainment methods have not been previously validated. NMSC cases arising from
patients served by a staff model medical group and diagnosed between 1 January 2007 and 31 December 2008
were identified from claims data using three ascertainment strategies. These claims data cases were then
compared with NMSC identified using natural language processing (NLP) of electronic pathology reports
(EPRs), and sensitivity, specificity, positive and negative predictive values were calculated. Comparison of claims
data–ascertained cases with the NLP demonstrated sensitivities ranging from 48 to 65% and specificities from 85
to 98%, with ICD-9-CM ascertainment demonstrating the highest case sensitivity, although the lowest specificity.
HMO health plan claims data had a higher specificity than all-payer claims data. A comparison of EPR and clinic
log registry cases showed a sensitivity of 98% and a specificity of 99%. Validation of administrative data to
ascertain NMSC demonstrates respectable sensitivity and specificity, although NLP ascertainment was superior.
There is a substantial difference in cases identified by NLP compared with claims data, suggesting that formal
surveillance efforts should be considered.
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INTRODUCTION
Skin cancer is becoming an increasing health burden (Athas
et al., 2003; Housman et al., 2003; Rogers et al., 2006). The
majority of these skin cancers are basal cell carcinoma (BCC)
and cutaneous squamous cell carcinoma (SCC), which are
commonly referred to collectively as nonmelanoma skin
cancer (NMSC), and represent the most common malignancy
in the United States. Annual incidence of NMSC is estimated
to be nearly equal to the incidence of all other cancers
combined (Housman et al. 2003; Jemal et al., 2010).
Previously, we defined and compared algorithms for
identifying NMSC using the computerized administrative
claims–based data set of a large health-care system provider
and its affiliated health maintenance organization (HMO;
Eide et al., 2010). Using chart review of claims data
algorithms examining International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) and
current procedural terminology codes (CPT), we demon-
strated positive predictive values (PPVs) ranging from 47% for
ICD-9-CM-ascertained cases to 95% for cases ascertained
with both ICD-9-CM and CPT codes in a random sample of
all-payer cases. NMSC cases were confirmed in 497% of
cases regardless of the ascertained method in a sample of
health-plan enrollees. The lack of tumor registry information,
as these cancers are excluded from common tumor sources,
including the Surveillance Epidemiology and End Results
(SEER) program, prohibited validation of the algorithms
against a gold-standard measure and an estimation of missed
true cases.
Validation of claims data algorithms for NMSC ascertain-
ment, including information on missed cases in claims
data, is paramount for standardizing the study of NMSC.
Capitalizing on health-system electronic pathology informa-
tion, which is integral to the e-surveillance of reportable
tumors to the local (SEER) tumor registry, we proposed to
ascertain NMSC cases similarly from electronic pathology
reports (EPRs). These electronic histopathology records
would then constitute a gold-standard comparison for cases
ascertained by claims data. The objective of this study was
to determine sensitivity, specificity, PPV, and negative
predictive value (NPV) of claims data algorithms to
ascertain NMSC cases, with validation against the health-
system EPR.
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RESULTS
From 1 January 2007 to 31 December 2008, there were
24,164 cases involving skin specimens processed by histo-
pathology as identified by the EPR in the all-payer popula-
tion. This included 4,883 unique NMSC cases. Comparison
of all-payer claims data NMSC ascertainment algorithms to
the EPR demonstrated sensitivities ranging from 48 to 64%
and specificities from 85 to 94%, with ICD-9-CM ascertain-
ment demonstrating the highest case sensitivity and the
combination of ICD-9-CM and CPT together obtaining the
highest specificity and PPV (Table 1).
In the HMO population, there were 15,297 total skin
specimen cases and 2,506 cases of NMSC ascertained from
claims data. When compared with the EPR, NMSC claims
data algorithm sensitivities ranged from 49 to 65% and
specificities from 96 to 98% (Table 2).
One clinic log site, which the EPR was cross-validated
against, submitted 4,614 total cutaneous cases during the
study period. This included 909 NMSC cases. The sensitivity,
specificity, and negative and PPVs for the clinic logbook site
and the EPR compared favorably, with all values 498%
(Table 3). The logbook clinic site, all-payer claims data was
comparable by NMSC ascertainment algorithm with the
entire health-system estimates (Table 4).
The reasons for discordance of cases ascertained from the
clinic logbook and the EPR were investigated. The majority of
EPR non-confirmed cases or false cases was attributable
to exclusion of residual cutaneous malignancy, likely on
re-excision (Table 5).
DISCUSSION
We present validation of previously defined claims data
NMSC ascertainment algorithms using the computerized
databases compared with the results from the use of natural
language processing (NLP) of electronic histopathology
records of a large health system. Cases of NMSC can be
ascertained in the health-system setting using adminis-
trative data with respectable sensitivity, specificity, NPVs
and PPVs, with higher case sensitivity using ICD-9-CM
ascertainment methods and higher specificity using both
ICD-9-CM and CPT together, which we hope will provide
interested investigators knowledge and direction as they
design secondary data studies. Our findings also further the
understanding of the capacity and limitations of using claims
data to identify and investigate NMSC.
The World Health Organization recognizes the difficulty
in ascertaining the incidence of NMSC, noting limited
registries capturing BCC and SCC, especially in North
Table 1. Identified and confirmed nonmelanoma skin cancer cases with sensitivity, specificity, NPV, and PPV
(2007–2008), all-payer claims data
Identification
algorithm
True
positive
cases
Identified
cases by
algorithm
Confirmed true
cases identified
by algorithm
Sensitivity
(95% CI)
Specificity
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
ICD-9-CM code alone 4,883 5,995 3,128 64.1 (62.7–65.4) 85.1 (84.6–85.6) 90.3 (89.9–90.8) 52.2 (50.9–53.4)
CPT code alone 4,883 5,541 3,078 63.0 (61.7–64.4) 87.2 (86.8–87.7) 90.3 (89.9–90.7) 55.5 (54.2–56.9)
Both ICD-9-CM
and CPT codes
4,883 3,441 2,335 47.8 (46.4–49.2) 94.3 (93.9–94.6) 87.7 (87.3–88.2) 67.9 (66.3–69.4)
Abbreviations: CI, confidence interval; CPT, current procedural terminology; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical
Modification; NPV, negative predictive value; PPV, positive predictive value.
Study population: large integrated health system, all-payer health-plan patients, southeastern MI, USA.
Standard: Co-Path electronic histopathology data.
Total skin pathology cases: 24,164.
Table 2. Identified and confirmed nonmelanoma skin cancer cases with sensitivity, specificity, NPV, and PPV by
algorithm (2007–2008), HMO-enrollee claims data
Identification
algorithm
True
positive
cases
Identified
cases by
algorithm
Confirmed true
cases identified
by algorithm
Sensitivity
(95% CI)
Specificity
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
ICD-9-CM code alone 2,506 2,209 1,639 65.4 (63.5–67.3) 95.5 (95.2–95.9) 93.4 (93.0–93.8) 74.2 (72.4–76.0)
CPT code alone 2,506 2,059 1,610 64.2 (62.4–66.1) 96.5 (96.2–96.8) 93.2 (92.8–93.7) 78.2 (76.4–80.0)
Both ICD-9-CM
and CPT codes
2,506 1,534 1,230 49.1 (47.1–51.0) 97.6 (97.4–97.9) 90.7 (90.2–91.2) 80.2 (78.2–82.2)
Abbreviations: CI, confidence interval; CPT, current procedural terminology; HMO, health maintenance organization; ICD-9-CM, International
Classification of Diseases, 9th Revision, Clinical Modification; NPV, negative predictive value; PPV, positive predictive value.
Study population: large integrated health system, HMO health-plan enrollees, southeastern MI, USA.
Standard: Co-Path electronic histopathology data.
Total skin pathology cases: 15,297.
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America (International Agency For Research On Cancer,
2008). It is a significant investment of time and resources
to initiate new or expanded traditional registries for
the ascertainment of BCC and SCC (Lamberg et al.,
2010). We believe that collaborative efforts of large US
HMOs, such as those that participate in the National
Cancer Institute funded Cancer Research Network (CRN),
which covers nearly 11 million individuals, have the
potential to provide high-quality, efficient NMSC ascer-
tainment in the United States (National Cancer Institute,
2010).
We previously reported algorithms for identifying NMSC
using the computerized administrative claims–based data set
of this same large US health-care system provider and its
affiliated HMO (Eide et al., 2010). NMSC patients who were
diagnosed between 1988 and 2007 were identified using
three algorithms: NMSC ICD-9-CM codes, NMSC treatment
CPT codes, or both ICD-9-CM and CPT codes. A subset of
charts was reviewed to verify NMSC diagnosis, including all
HMO enrollee members’ EMRs in 2007, and PPV for NMSC
were calculated (with sensitivity, specificity, and NPV unable
to be predicted). A random sample of all years, and all payers
Table 3. Confirmed and identified nonmelanoma skin cancer cases with sensitivity, specificity, NPV, and PPV
(2007–2008), electronic pathology record and logbook clinic site
Standard
source
Confirmed cases
by chart review
Identified
by method
Sensitivity
(95% CI)
Specificity
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
EPR 894 909 98.3 (97.5–99.2) 99.6 (99.4–99.8) 99.6 (99.4–99.8) 98.2 (97.4–99.1)
Clinic logbook 894 910 98.2 (97.4–99.1) 99.5 (99.3–99.7) 99.6 (99.4–99.8) 98.0 (97.1–98.9)
Abbreviations: CI, confidence interval; EPR, electronic histopathology record; NPV, negative predictive value; PPV, positive predictive value.
Study population: large integrated health system, all-payer health-plan patients, logbook clinic site, southeastern MI, USA with Co-Path EPR.
Total skin pathology cases: 4,614.
Standard: chart review of all identified cases regardless of ascertainment method.
Table 4. Total pathology skin specimens, identified and confirmed nonmelanoma skin cancer cases with sensitivity,
specificity, NPV, and PPV, 2007–2008, clinic log data
Identification
algorithm
Identified cases
by algorithm
Confirmed
cases
Sensitivity
(95% CI)
Specificity
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
ICD-9-CM code alone 626 540 59.4 (56.2–62.6) 97.7 (97.2–98.2) 90.7 (89.8–91.6) 86.3 (83.6–89.0)
CPT code alone 544 501 55.1 (51.9–58.3) 98.8 (98.5–99.2) 90.0 (89.0–90.9) 92.1 (89.8–94.4)
Both ICD-9-CM and CPT codes 487 462 50.8 (47.6–54.1) 99.3 (99.1–99.6) 89.2 (88.2–90.1) 94.9 (92.9–96.8)
Abbreviations: CI, confidence interval; CPT, current procedural terminology; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical
Modification; NPV, negative predictive value; PPV, positive predictive value.
Study population: large integrated health system, single clinical site, southeastern MI, USA.
Standard: Co-Path electronic histopathology data.
Total skin pathology cases: 4,614.
Table 5. Characteristics of false cases of NMSC identified by either clinic log or EPR information (2007–2008)
Unconfirmed cases
Reason
EPR
(N=15)
Clinic log
(N=16)
Missing information (omission or abstractor error possible) 5 0
Basal cell or squamous cell carcinoma1 2 11
Rare cutaneous carcinomas not included in electronic search (e.g., ‘‘sebaceous carcinoma’’, ‘‘desmoplastic epithelial tumor’’) 0 2
Suggestion or inconclusive description of cutaneous malignancy (e.g., ‘‘basaloid epitheloid islands’’, ‘‘suggestive of’’) 1 2
Exclusion of cutaneous malignancy (e.g., ‘‘scar, negative for’’, ‘‘negative for’’, ‘‘no residual’’) 6 0
Different physical clinical location than clinic log site itself1 1 1
Abbreviations: EPR, electronic histopathology record; NMSC, nonmelanoma skin cancer.
1Patient was flagged as present in both columns due to nonmatching date of service differences (N=2; of which one had different clinic site and one was
a squamous cell carcinoma).
Study population: large integrated health system, single clinical site and Co-Path electronic histopathology record data, southeastern MI, USA.
www.jidonline.org 2007
MJ Eide et al.
Validation of NMSC Claims Data Algorithms
were selected for chart review, with PPVs of 47.0% for ICD-
9-CM-identified patients, 73.4% for CPT-identified patients,
and 94.9% identified with both codes required. All charts
from HMO health-plan enrollees in 2007 were reviewed with
PPVs of 96.5% for ICD-9-CM-identified patients, 98.3% for
CPT-identified patients, and 98.7% identified with both codes
(Eide et al., 2010). In our current investigation, we utilized EPR
NLP information to determine sensitivity, specificity, NPVs
and PPVs, further advancing the establishment of methodol-
ogy for ascertaining NMSC in claims data. Differences in
PPVs can partly be attributed to difficulty with administrative
data date information, which does not always correpond to
actual practice. Our findings validate claims data, but also
highlight its limitations, suggesting that NLP may be a more
accurate ascertainment method.
We are excited to present the validation of NMSC billing
claims data against a gold standard–type quality data source.
The absence of a population-based tumor registry has
hampered the evolution of administrative claims data to
study NMSC. As a comprehensive health system, we were
able to use NLP and our electronic histopathology reports,
which routinely report other ‘‘reportable’’ tumors to our
tumor registry and the local SEER registry, to identify NMSC,
and this EPR information was then utilized as a standard to
determine sensitivity and specificity. We believe that this
study makes an important additional contribution to estab-
lishing validated, accepted methods for ascertaining cases of
NMSC with secondary data analysis, as well as highlighting
their limitations. Although the implementation of ICD-10 will
provide better claims data estimates of SCC and BCC impact,
we believe that our study supports using caution when
interpreting claims data for NMSC ascertainment: claims data
may significantly overestimate actual disease burden, with up
to half of ICD-9 ascertained cases found to be false.
We note several limitations to our investigation. This study
is limited to a single institution, and should be validated at
other institutions or data sets to ensure that it is generalizable.
Because we have an open health system, there is the
possibility of incomplete claims from patients referred from
outside clinicians to the health system or health-plan patients
who elected for treatment by an outside, non-HMO provider.
Although this is an issue in any open-access US health
system, in a subset, we limited our HMO enrollee analysis
to patients who had continuous health-plan enrollment
during the period of interest to minimize this potential.
Historically, NLP can be hampered by negation errors;
however, in a setting such as our HMO system, which strives
for standardized reporting, our NLP case ascertainment was
very robust and validated against a clinic log registry. Finally,
the low specificity of the use of administrative claims data
using ICD-9-CM, especially in all-payer claims data may be
partially due to the possibility of an intervening visit (between
biopsy and definitive treatment procedure). This limitation
would not be expected to improve with the further
implementation of ICD-10 in the United States. These
intervening visits would not impact EPR ascertainment and
may partly contribute to the superior specificity of EPR NLP
(Eide et al., 2010).
Conclusions
We present our findings demonstrating the sensitivity,
specificity, and predictive values of administrative claims
data algorithms to ascertain NMSC with validation by com-
parison with the EPRs of a large health system. Considering
the substantial difference in cases identified by EPR NLP
compared with claims data, we suggest that formal surveil-
lance efforts at the state or national level should be
considered and readdressed, as expansion of ICD-9-CM
codes in ICD-10 to include unique identifiers for BCC and
SCC will not equate to SEER or other tumor registry
surveillance accuracy. These algorithms need to be evaluated
in other settings and institutions, ideally with similar capacity
for validation against electronic histopathology information.
The use of EPR NLP in a setting such as the Cancer Research
Network’s large, diverse population-based, HMO consortium
may be a potential alternative to a traditional registry.
MATERIALS AND METHODS
Patients were identified from outpatient health-plan administrative
claims data from a large southeastern Michigan HMO and from an
outpatient database of individuals with other means of payment seen
by the same health-system providers belonging to a salaried medical
group. The health system, which consists of 6 hospitals and 32
ambulatory clinics dispersed throughout a tri-county area, reflects
the diverse population of the metropolitan area, with the following
exceptions. With 13% of health-plan enrollees over the age of 65
years and 30% younger than age 24 years old, the HMO population
has a large working-age population, with corresponding modest
increases in full-time employment status, household income, and
improved general health. As of 2006, the staff model health plan
used for this study had an enrollment of 295,000, with a 1-year
retention of 84% and a 5-year retention of 56% (National Cancer
Institute, 2010). This HMO is a member of the Cancer Research
Network (CRN), which is a consortium of integrated health-care
systems who have joined efforts for the conduction of collaborative
research on preventive, curative, and supportive interventions for
major cancers among diverse populations and health systems. The
CRN, which was established in 1999, currently consists of 14 health
plans, with nearly 11 million enrollees, and is distinguished by their
longstanding commitment to prevention and research. Further detail
of this HMO, health-plan enrollee demographic information, and
generalizability to the surrounding communities has been previously
described (Eide et al., 2010). This study was approved by expedited
review by the institutional review board.
The gold-standard comparison for algorithm validation was
obtained from the EPRs of the health system. Total pathology
specimen estimates between 1 January 2007 and 31 December 2008
were obtained leveraging the NLP algorithm within the CoPathPlus
Anatomic Pathology Laboratory Information System3 (Sunquest
Information Systems, Tucson, AZ). The natural language query
combined both structured data fields and free text query, including
negation statements and combinatorial algebraic SQL statements.
A controlled vocabulary was used and included text strings that
matched the diagnostic entities of interest, as well as pertinent tissue
types in combination, to create higher specified data returns. The
text query was limited to skin tissue samples only for inclusion, and
no negation statements were necessary. Each individual query was
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combined with subsequent queries using ‘‘or’’ statements to
ascertain all cases of interest. From CoPathPlus, the following
cutaneous malignancies were then identified using free text retrieval
capacity from the final diagnosis cell, using the following terms:
‘‘Basal cell carcinoma’’ (including ‘‘Fibroepithelioma of Pinkus’’
also known as (AKA) ‘‘Pinkus Tumor’’), ‘‘Microcystic adnexal
carcinoma,’’ ‘‘Basosquamous carcinoma,’’ ‘‘Squamous cell carcino-
ma’’ (including ‘‘Clear cell squamous cell carcinoma’’ AKA ‘‘clear
cell carcinoma of the skin’’, ‘‘Spindle cell squamous cell carcinoma’’
AKA ‘‘spindle cell carcinoma,’’ and ‘‘Marjolin’s ulcer’’ and
‘‘keratoacanthoma’’), ‘‘Verrucous carcinoma’’ (including ‘‘Carcino-
ma cuniculatum’’ and ‘‘Ackerman tumor’’), and Squamous cell
carcinoma in situ (including ‘‘Bowen disease’’, ‘‘Bowen’s disease’’
and ‘‘Erythroplasia de queyrat’’). The text resulting from the CoPath
query was further processed using SAS (SAS Institute, Cary, NC) to
format data and apply coding logic and classify by histologic type. A
sample of EPR data capture was cross-validated against a hardcopy
case-log registry book (‘‘clinic log’’) maintained at one clinic site
within the health system.
Outpatient cases of NMSC for the study period were ascertained
from outpatient administrative claims data using ICD-9-CM diag-
nosis and CPT procedural code algorithms (Eide et al., 2010). The
ICD-9-CM diagnosis (for malignant neoplasm of the skin) and CPT
procedural code (for excision malignant lesion, destruction of
malignant lesion, and chemosurgery/Mohs micrographic technique)
algorithms and characteristics of false-positive cases has been
previously described in detail; please refer Eide et al. (2010) for
full description and definition of codes utilized. ICD9 and CPT4
claims data entries were matched to the EHR by visit number to
identify incident cases.
Sensitivity, specificity, NPV, and PPV of each algorithm along
with corresponding 95% confidence intervals were calculated and
compared with the gold standard electronic pathology record.
Analyses examined all-payer cases (regardless of health plan),
health-plan enrollee’s cases only, and the cases ascertained from
the clinic log.
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